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doi:10.1Objective: The application of extracorporeal membrane oxygenation in adults has been increasing, but infections
occurring during extracorporeal membrane oxygenation use are rarely described.
Methods:We retrospectively analyzed the prospectively collected data on nosocomial infection surveillance of
334 patients aged 16 years or more undergoing their first extracorporeal membrane oxygenation for more than 48
hours at a university hospital from 1996 to 2007 for respiratory (20.4%) and cardiac (79.6%) support.
Results:During a total of 2559 extracorporeal membrane oxygenation days, 55 episodes of infections occurred in
45 patients (13.5%), including 38 bloodstream (14.85 per 1000 extracorporeal membrane oxygenation days), 6
surgical site, 4 respiratory tract, 3 urinary tract, and 4 other infections. Stenotrophomonas maltophilia (16.7%)
and Candida species (14.6%) were the predominant blood isolates. In stepwise logistic regression analysis, lon-
ger duration of extracorporeal membrane oxygenation use (odds ratio 1.003; 95% confidence interval, 1.001–
1.005; P ¼ .004), mechanical complications (odds ratio, 4.849; 95% confidence interval, 1.569–14.991;
P ¼ .006), autoimmune disease (odds ratio, 6.997; 95% confidence interval, 1.541–31.766; P ¼ .012), and ve-
novenous mode (odds ratio, 4.473; 95% confidence interval, 1.001–19.977; P¼ .050) were independently asso-
ciated with a higher risk for infections during extracorporeal membrane oxygenation use. Overall in-hospital
mortality was 68.3%, and its independent risk factors included older age (odds ratio, 1.037; 95% confidence in-
terval, 1.021–1.054; P< .001), neurologic complications (odds ratio, 51.153; 95% confidence interval, 6.773–
386.329; P< .001), and vascular complications (odds ratio, 1.922; 95% confidence interval, 1.112–3.320;
P< .001), but not infections during extracorporeal membrane oxygenation use.
Conclusions: Bloodstream infection was the most common infection during extracorporeal membrane oxygen-
ation use. Duration of extracorporeal membrane oxygenation, mechanical complications, autoimmune disease,
and venovenous mode seemed to be independently associated with infections. (J Thorac Cardiovasc Surg
2010;140:1125-32)Supplemental material is available online.P
MExtracorporeal membrane oxygenation (ECMO) was first
reported for adult respiratory distress syndrome in 1972.1
Subsequently, ECMO was gradually accepted as a treatment
modality for neonatal, pediatric, and adult patients with re-
spiratory or cardiac failure who fail to respond to maximal
medical therapy. Currently, more than 24,000 neonates,e Department of Internal Medicine,a Department of Surgery,b and Center for
tion Control,c National Taiwan University Hospital and National Taiwan Uni-
y College of Medicine, Taipei, Taiwan; and Department of Biostatistics,d
uate School of Public Health, University of Pittsburgh, Pittsburgh, Pa.
ures: None.
d for publication Oct 19, 2009; revisions received Jan 18, 2010; accepted for
cation July 4, 2010; available ahead of print Aug 16, 2010.
for reprints: Yee-Chun Chen, MD, PhD, Division of Infectious Diseases,
rtment of Internal Medicine, National Taiwan University Hospital, No. 7,
g-Shan South Road, Taipei, 100, Taiwan (E-mail: yeechunchen@gmail.com).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.07.017
The Journal of Thoracic and Car7000 children, and 2000 adults have been treated with
ECMO.2 Although its use is relatively controversial in
adults, ECMO has been gradually used as cardiac support
in various clinical settings, such as postcardiotomy cardio-
genic shock after cardiac surgery,3 bridge to heart transplan-
tation,4 fulminant myocarditis,5 and assistance for
cardiopulmonary resuscitation (CPR).6
InfectionsoccurringduringECMOuse increasemortality in
neonatal or pediatric populations, butwhether they have a sim-
ilar impact on adults has rarely been reported.7-10 Thus, we
assessed the occurrence, type, causative pathogens, and risk
factors of infections during ECMO use as respiratory or
cardiac support in adults at an extracorporeal life-support refer-
ral center. Risk factors associated with in-hospital mortality
were also analyzed.
MATERIALS AND METHODS
Setting and Study Population
National Taiwan University Hospital, a university hospital with a 2200-
bed capacity, provides both primary and tertiary referral care. It is also an
extracorporeal life-support referral center.4,11 The first ECMO at this
hospital was in August of 1994.3 In the following years, ECMO was per-
formed approximately 30 to 60 times per year before 2003 and approxi-
mately 100 or more times per year since 2003. A computerized casediovascular Surgery c Volume 140, Number 5 1125
Abbreviations and Acronyms
APACHE II ¼ Acute Physiology and Chronic
Health Evaluation II
CI ¼ confidence interval
CPR ¼ cardiopulmonary resuscitation
ECMO ¼ extracorporeal membrane
oxygenation
IABP ¼ intra-aortic balloon pump
OR ¼ odds ratio
VV ¼ venovenous
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Mrecord form was used to prospectively collect the demographic and clinical
data of patients undergoing ECMO, including age, gender, underlying dis-
eases, baseline heart function by NewYork Heart Association classification,
dates of admission, infections before ECMO initiation, and conditions dur-
ing ECMO use (Acute Physiology and Chronic Health Evaluation II
[APACHE II] at ECMO initiation and dates, locations, indications, modes,
complications, and outcomes of ECMO use). We also recorded the require-
ment of an intra-aortic balloon pump (IABP) or CPR during hospitalization
and dates of discharge or in-hospital death.
Patients were eligible for the present study if they (1) were aged 16 years
or more; (2) underwent ECMO between January 1, 1996, and December 31,
2007; and (3) underwent ECMO for respiratory or circulatory support. Pa-
tients were excluded if (1) ECMO was initiated at other hospitals, (2)
ECMO use was less than 48 hours because of inadequate ECMO exposure
for evaluation of infections during ECMO use, or (3) this was not their first-
time ECMO use. After ECMO initiation, patients were followed until dis-
charge or death during hospitalization. Infections before ECMO initiation
were defined as newly emerging or uncontrolled infections within 7 days
before ECMO initiation.
Hospital-wide active surveillance of nosocomial infections at National
Taiwan University Hospital has been conducted since 1981.12 Nosocomial
infections were defined as the criteria proposed by the Centers for Disease
Control and Prevention definition.13 A computerized case record form was
used to prospectively collect the data of patients with nosocomial infections,
including age; gender; and dates, sites, and causative pathogens of nosoco-
mial infections. The data of infections occurring in the period from the ini-
tiation to the removal of ECMO and caused by pathogens different from
those of infections within 7 days before ECMO initiation were extracted
for analysis. Patients’ medical charts were also reviewed to ensure com-
pleteness of data collection.
At ECMO initiation, antibiotic prophylaxis with ceftazidime and vanco-
mycin was prescribed to patients without antibiotic use. In patients who had
already been taking antibiotics, antimicrobial agents were maintained or
modified empirically at the discretion of the attending clinical team. During
ECMO use, antibiotics were adjusted according to clinical situations or
culture results. The institutional review board of the hospitals approved
the study and waived for the need of informed consent.
Statistical Analysis
All statistical analyses were performed using SPSS software version 16.0
(SPSS Inc, Chicago, Ill). Categoric variables were compared using the chi-
square or Fisher’s exact test, whereas continuous variables were compared
using the Student t test or Mann–Whitney U test and were expressed as
mean standard deviation or median with range. A stepwise logistic regres-
sionmodel was built to identify independent variables associatedwith infec-
tions occurring during ECMO use and in-hospital death, respectively. All
tests were 2-tailed.1126 The Journal of Thoracic and Cardiovascular SurRESULTS
A total of 569 adults underwent 594 cases of ECMO for
respiratory or cardiac support during the study period. Of
the 594 cases of ECMO, 260 were excluded for the follow-
ing reasons: ECMOuse for less than 48 hours in 166, ECMO
initiated at other hospitals in 62, and not the first-time use of
ECMO in 32. The demographics of the remaining 334
ECMO cases in 334 patients are presented in Table 1.
Fifty-five episodes of infection occurred in 45 patients
(13.5%, 45/334) during ECMO use, including 38 episodes
(69.1%, 38/55) of bloodstream infections, 6 (10.9%, 6/55)
surgical site infections, 4 (7.3%, 4/55) respiratory tract in-
fections, 3 (5.5%, 3/55) urinary tract infections, 2 (3.6%,
2/55) skin and soft tissue infections, and 2 (3.6%, 2/55)
catheter infections.
A total of 48 pathogens were isolated from the blood, and
gram-negative bacteria (68.8%, 33/48) were most common,
followed by gram-positive bacteria (16.7%, 8/48) and fungi
(14.6%, 7/48) (Table 2). Stenotrophomonas maltophilia,
Candida species, and Pseudomonas aeruginosa were the 3
predominant blood isolates; Staphylococcus aureus was
the main gram-positive pathogen. The median interval
from ECMO initiation to the onset of bloodstream infections
was 8 days (range, 2–32 days). At the onset of bloodstream
infections, patients had been hospitalized for a median dura-
tion of 20 days (range, 2–89 days).
In the 334 patients, the total duration of ECMO use was
61,424 hours (or 2559 days) and overall rate of bloodstream
infection was 14.85 episodes per 1000 ECMO days. Rate of
bloodstream infectionwas 13.83, 23.78, 24.45, and 14.65 ep-
isodes per 1000 ECMO days in patients undergoing ECMO
formore than 2 to 10 days,more than 10 to 20 days,more than
20 to 30 days, andmore than 30 days, respectively (Figure 1).
Surgical site infection developed a median of 23 days
(range, 8–35 days) after ECMO initiation, and gram-
negative bacteria accounted for 70% of the causative path-
ogens (Table 2). Respiratory tract infections occurred at
a median of 5 days (range, 5–6 days) of ECMO use, and
80% were caused by gram-negative bacteria. Urinary tract
infection developed on days 10, 13, and 13 of ECMO use,
respectively. Infections were due to Escherichia coli in 1 ep-
isode and yeast-organisms in 2 episodes. Skin and soft tissue
infection occurred on days 2 and 22 of ECMO use, respec-
tively, and both patients survived. Catheter infection devel-
oped in 2 patients on days 6 and 14 of ECMO use.
Of the 9 isolates of S maltophilia, 11.1% (1/9) were re-
sistant to trimethoprim/sulfamethoxazole, 28.5% (2/7) were
resistant to ticarcillin/clavulanate, 33.3% (3/9) were nonsus-
ceptible to ciprofloxacin, 44.4% (4/9) were nonsusceptible
to ceftazidime, and all were nonsusceptible to cefepime (9/
9). Of the 6 isolates of P aeruginosa, none were resistant to
gentamicin; 16.7% (1/6) were resistant to ciprofloxacin;
20% (1/5) were resistant to piperacillin/tazobactam; 33.3%
(2/6) were resistant to ceftazidime, cefepime, or aztreonam;gery c November 2010
TABLE 1. Demographic comparison between 45 patients with and 289 patients without infections occurring during extracorporeal membrane
oxygenation use
Characteristics Total Infections No infections P value
Patient no. 334 45 289
Men,% (n) 68.0 (227) 73.3 (33) 67.1 (194) .407
Age, y (mean  SD) 51  17 47  15 52  17 .099
16–35 y,% (n) 21.6 (72) 28.9 (13) 20.4 (59) .140
36–55 y 35.0 (117) 35.6 (16) 34.9 (101)
56–75 y 38.6 (129) 35.6 (16) 39.1 (113)
76 y 4.8 (16) 0 (0) 5.5 (16)
Underlying diseases,% (n)
Coronary artery disease 45.2 (151) 40.0 (18) 46.0 (133) .450
Hypertension 28.7 (96) 28.9 (13) 28.7 (83) .981
Diabetes mellitus 26.3 (88) 26.7 (12) 26.3 (76) .958
Valvular heart disease 13.2 (44) 8.9 (4) 13.8 (40) .361
Cardiomyopathy 11.1 (37) 11.1 (5) 11.1 (32) .999
Transplantation 9.3 (31) 6.7 (3) 9.7 (28) .709
Cerebrovascular accident 6.9 (23) 4.4 (2) 7.3 (21) .705
Malignancy 6.6 (22) 8.9 (4) 6.2 (18) .729
Congenital heart disease 4.5 (15) 4.4 (2) 4.5 (13) .999
End-stage renal disease 4.2 (14) 8.9 (4) 3.5 (10) .197
Autoimmune disease* 3.0 (10) 11.1 (5) 1.7 (5) .003
Othersy 7.2 (24) 13.3 (6) 6.2 (18) .160
Indication of ECMO use,% (n)
Respiratory support 20.4 (68) 37.8 (17) 17.6 (51) .002
Infection associated 60.3 (41/68) 70.6 (12/17) 56.9 (29/51) .317
Non-infection associated 39.7 (27/68) 29.4 (5/17) 43.1 (22/51)
Cardiac support 79.6 (266) 62.2 (28) 82.4 (238) .002
Postcardiotomyz 30.1 (80/266) 17.9 (5/28) 31.5 (75/238) .136
Acute myocardial infarction 29.7 (79/266) 32.1 (9/28) 29.4 (70/238) .765
Cardiomyopathy 15.4 (41/266) 28.6 (8/28) 13.9 (33/238) .078
Acute myocarditis 10.5 (28/266) 3.6 (1/28) 11.3 (27/238) .346
PH and RH failure 2.3 (6/266) 10.7 (3/28) 1.3 (3/238) .017
Septic shock 3.0 (8/266) 7.1 (2/28) 2.5 (6/238) .201
Othersx 9.0 (24/266) 0 (0/28) 10.1 (24/238) .158
SD, Standard deviation; ECMO, extracorporeal membrane oxygenation; PH, pulmonary hypertension; RH, right heart. *Autoimmune disease included systemic lupus erythema-
tosus, Wegener’s granulomatosis, dermatomyositis, antiphospholipid syndrome, and scleroderma with vasculitis. yOthers included trauma, primary pulmonary hypertension, liver
cirrhosis, and chronic obstructive pulmonary disease. zPostcardiotomy ¼ ECMO use for postcardiotomy cardiogenic shock in patients undergoing cardiac operations, including
coronary bypass grafting in 40% (32/80), heart transplantation in 25% (20/80), heart valvular operations in 18.8% (15/80), and others in 16.2% (13/80, including pericardiotomy/
pericardiectomy, correction of congenital heart disease, aortic operation, and pulmonary artery endarterectomy). xOthers included acute rejection, congenital heart disease, and
unidentified cardiac diseases.
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Mand 40% (2/5) were resistant to carbapenem. Of the 5 isolates
of Acinetobacter baumannii, 60% (3/5) were nonsusceptible
to carbapenem; 80% (4/5) were nonsusceptible to ceftazi-
dime, cefepime, or ciprofloxacin; and all (5/5) were resistant
to gentamicin.
Of the 21 isolates of enteric bacteria that included 7 Enter-
obacter species, 6 Klebsiella pneumoniae, 6 E coli, 1 Aero-
monas caviae, and 1 Serratia marcescens, 62% (13/21)
were nonsusceptible to cefotaxime, 33.3% (7/21) were re-
sistant to gentamicin, 19% (4/21) were resistant to fluoro-
quinolone, 14.3% (3/21) were resistant to cefepime, and
none (0/21) were resistant to carbapenem. Of the 7 isolates
of S aureus, 85.7% (6/7) were resistant to oxacillin and gen-
tamicin, and 42.9% (3/7) were resistant to trimethoprim/
sulfamethoxazole. All 3 isolates of coagulase negativeThe Journal of Thoracic and Carstaphylococci were resistant to oxacillin, and the 2 isolates
of Enterococcus faecalis were both susceptible to penicillin.
Compared with patients without infections occurring
during ECMO use, those with infections were more likely
to have autoimmune disease as the underlying disease
(11.1% vs 1.7%, P ¼ .003); to undergo ECMO for respira-
tory support (37.8% vs 17.6%, P¼ .002) or pulmonary hy-
pertension and right-sided heart failure as indication of
cardiac support (10.7% vs 1.3%, P ¼ .017); to have infec-
tions before ECMO initiation (37.8% vs 17.0%, P ¼ .001);
to receive venovenous (VV) mode (37.8% vs 14.0%,
P< .001); to have a longer duration of ECMO use (360 
237 vs 157 165 hours, P<.001); and to develop mechan-
ical (91.1% vs 56.4%, P< .001) or pulmonary complica-
tions (17.8% vs 5.2%, P ¼ .005) (Tables 1 and 3).diovascular Surgery c Volume 140, Number 5 1127
TABLE 2. Isolates of bloodstream, surgical site, respiratory tract, and urinary tract infections during extracorporeal membrane oxygenation use
BSI (48 isolates) % (n) SSI (10 isolates) % (n) RTI (5 isolates) % (n) UTI (3 isolates) % (n)
Gram-negative bacteria 68.8 (33) 70.0 (7) 80 (4) 33.3 (1)
Stenotrophomonas maltophilia 16.7 (8) Enterobacter cloacae 30.0 (3) Burkholderia cepacia
complex
40.0 (2) E coli 33.3 (1)
Pseudomonas aeruginosa 12.5 (6) Klebsiella oxytoca 10.0 (1) Sphingomonas
paucimobilis
20.0 (1)
Klebsiella pneumoniae 10.4 (5) E coli 10.0 (1) Serratia marcescens 20.0 (1)
Acinetobacter baumannii 10.4 (5) Aeromonas caviae 10.0 (1)
Enterobacter species 8.3 (4) S maltophilia 10.0 (1)
Escherichia coli 6.3 (3)
Burkholderia cepacia complex 2.1 (1)
Bacteroides thetaiotaomicron 2.1 (1)
Gram-positive bacteria 16.7 (8) 20.0 (2) 20 (1) 0 (0)
Staphylococcus aureus 8.3 (4) S aureus 20.0 (2) S aureus 20.0 (1)
Enterococcus faecalis 4.2 (2)
Coagulase-negative staphylococci 4.2 (2)
Fungi 14.6 (7) 10.0 (1) 0 (0) 66.7 (2)
Candida albicans 8.3 (4) Candida parapsilosis 10.0 (1) Yeast-like
organism
66.7 (2)
Candida tropicalis 4.2 (2)
Candida glabrata 2.1 (1)
BSI, Bloodstream infection; SSI, surgical site infection; RTI, respiratory tract infection; UTI, urinary tract infection.
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MA stepwise logistic regression model was constructed to
determine the independent role of duration of ECMOuse, in-
fection before ECMO initiation, ECMO use as respiratory
support, receipt of VV mode, development of mechanical
or pulmonary complications, and underlying disease with
autoimmune disease as contributors to occurrence of infec-
tions during ECMO use (Table 4). Longer duration of
ECMO use (odds ratio [OR], 1.003; 95% confidence inter-
val [CI], 1.001–1.005; P ¼ .004], mechanical complicationFIGURE 1. Rates of bloodstream infection among patients undergoing ECMOw
oxygenation.
1128 The Journal of Thoracic and Cardiovascular Sur(OR, 4.849; 95% CI, 1.569–14.991; P ¼ .006), receipt of
VV mode (OR, 4.473; 95% CI, 1.001–19.977; P ¼ .050),
and autoimmune disease (OR, 6.997; 95% CI, 1.541–
31.766; P ¼ .012) were independently associated with
a higher risk for infections occurring during ECMO use
(Table 4). Infections before ECMO initiation, ECMO use
for respiratory support, and development of pulmonary com-
plications were not independently associated with occur-
rence of infections during ECMO use.ho were stratified by duration of ECMO. ECMO, Extracorporeal membrane
gery c November 2010
TABLE 3. Comparison of extracorporeal membrane oxygenation use between patients with and without infections occurring during
extracorporeal membrane oxygenation use
Total Infections No infections P value
Patient no. 334 45 289
IABP during hospitalization,% (n) 58.4 (195) 46.7 (21) 60.2 (174) .086
CPR during hospitalization,% (n) 49.4 (165) 40.0 (18) 50.9 (147) .175
Infection before ECMO initiation,% (n) 19.8 (66) 37.8 (17) 17.0 (49) .001
Severity of disease at ECMO initiation
APACHE II score, mean  SD 17  7 16  7 17  7 .504
20,% (n) 31.4 (105) 28.9 (13) 31.8 (92) .692
Duration of hospitalization before
ECMO initiation, d, mean  SD
11.3  26.0 13.2  17.8 11.0  27.0 .595
ECMO use at admission,% (n) 26.9 (90) 17.8 (8) 28.4 (82) .136
1 wk of hospitalization 68.3 (228) 57.8 (26) 69.9 (202) .134
2 and>1 wk of hospitalization 10.2 (34) 8.9 (4) 10.4 (30)
>2 wk of hospitalization 21.6 (72) 33.3 (15) 19.7 (57)
Mode of ECMO,% (n)
Venoarterial 80.3 (265/330) 60.0 (27/45) 83.5 (238/285) <.001
Venovenous 17.3 (57/330) 37.8 (17/45) 14.0 (40/285) <.001
Duration of ECMO, h, mean  SD 184  188 360  237 157  163 <.001
184 h and>48 h,% (n) 69.2 (231) 26.7 (12) 75.8 (219) <.001
>184 h 30.8 (103) 73.3 (33) 24.2 (70)
Complications,% (n)
Mechanical* 61.1 (204) 91.1 (41) 56.4 (163) <.001
Hemorrhagey 49.4 (165) 62.2 (28) 47.4 (137) .064
Pulmonaryz 6.9 (23) 17.8 (8) 5.2 (15) .005
Cardiac tamponade 9.9 (33) 4.4 (2) 10.7 (31) .296
Vascularx 41.6 (139) 37.8 (17) 42.2 (122) .574
Outcomes of ECMO,% (n)
ECMO removal and discharge 27.8 (93) 24.4 (11) 28.4 (82) .075
Bridge to VAD or heart transplantation 7.5 (25) 2.2 (1) 8.3 (24)
Death with ECMO use 40.7 (136) 57.8 (26) 38.1 (110)
Death after ECMO removal 24.0 (80) 15.6 (7) 25.3 (73)
Death,% (n) 68.3 (228) 75.6 (34) 67.1 (194) .259
1 wk of ECMO initiation 38.6 (88/228) 23.5 (8/34) 41.2 (80/194) .147
2 and>1 wk of ECMO initiation 26.3 (60/228) 32.4 (11/34) 25.3 (49/194)
>2 wk of ECMO initiation 35.1 (80/228) 44.1 (15/34) 33.5 (65/194)
IABP, Intra-aortic balloon pump; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; SD, standard deviation; VAD, ventricular assist device.
*Mechanical complications included oxygenator failure; pump malfunction; heater dysfunction; clot of oxygenator, hemofilter, and other sites; connector crack; and so forth.
yHemorrhage complications included gastrointestinal hemorrhage, cannulation site bleeding, surgical site bleeding, and hemolysis. zPulmonary complications included pneumo-
thorax and pulmonary hemorrhage. xVascular complications included digital gangrene, dysfunction of reperfusion catheter, and fasciotomy.
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MOutcome
At the end of follow-up, overall mortality was 68.3%:
75.6% in patients with infections and 67.1% in patients
without infections occurring during ECMO use (P ¼ .259)
(Table 4). The death rate of patients with bloodstream, sur-
gical site, and respiratory tract infections was 88.2% (30/
34), 83.3% (5/6), and 75.0% (3/4), respectively. Compared
with patients who survived, patients who died at the end of
follow-up were older andmore likely to have coronary artery
disease or diabetes mellitus; to undergo ECMO with the in-
dication of cardiac support for acute myocardial infarction;
to require CPR during hospitalization; to initiate ECMO in
the second week of hospitalization; to have higher APACHE
II score; and to have neurologic, metabolic, or vascular com-
plications (Tables E1 and E2). In addition, patients who diedThe Journal of Thoracic and Carwere less likely to have cardiomyopathy as the underlying
disease, to have a baseline heart function of New York
Heart Association class I, to have acute myocarditis as an
indication of ECMO support, or to undergo ECMO in the
first week of hospitalization than patients who survived
(Tables E1 and E2). Infections before or during ECMO
use were not associated with in-hospital mortality.
By using stepwise logistic regression analysis with vari-
ables in Tables E1 and E2 significant at P less than .05 in
the model (ie, age, underlying diseases, baseline heart
function, ECMO indications, CPR during hospitalization,
APACHE II score, duration of hospitalization before ECMO
initiation, and complications of ECMO use), only older age
(OR, 1.037; 95% CI, 1.021–1.054; P< .001), neurologic
complications (OR, 51.153; 95% CI, 6.773–386.329;diovascular Surgery c Volume 140, Number 5 1129
TABLE 4. Variables associated with infections occurring during extracorporeal membrane oxygenation use by stepwise logistic regression model
Variables Reference OR (95% CI) P value
Duration of ECMO use Continuous variable 1.003 (1.001–1.005) .004
Infections before ECMO initiation No infections before ECMO initiation 1.782 (0.721–4.402) .211
Respiratory support Cardiac support 0.350 (0.072–1.688) .191
Venovenous mode Venoarterial mode 4.473 (1.001–19.977) .050
Mechanical complication* No mechanical complication 4.849 (1.569–14.991) .006
Pulmonary complicationy No pulmonary complication 1.694 (0.545–5.264) .362
Autoimmune diseasez No autoimmune disease 6.997 (1.541–31.766) .012
OR, Odds ratio; CI, confidence interval; ECMO, extracorporeal membrane oxygenation. *Mechanical complications included oxygenator failure; pump malfunction; heater dys-
function; clot of oxygenator, hemofilter, and other sites; connector crack; and so forth. yPulmonary complications included pneumothorax and pulmonary hemorrhage.
zAutoimmune disease included systemic lupus erythematosus, Wegener’s granulomatosis, dermatomyositis, antiphospholipid syndrome, and scleroderma with vasculitis.
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MP< .001), and vascular complications (OR, 1.922; 95% CI,
1.112–3.320; P< .001) were independently associated with
a higher risk for death, whereas ECMO initiation within 1
week of hospitalization (OR, 0.291; 95% CI, 0.160–0.530;
P< .001) was significantly associated with a lower risk for
mortality. Underlying diseases, baseline heart function,
indications of ECMO use, CPR during hospitalization, and
higher APACHE II score were not independently associated
with death at the end of follow-up.
DISCUSSION
In the literature, incidence of infections occurring during
ECMO use ranges widely from 3.5% to 45.1%,8-10,14,15
and bloodstream infection is most common, occurring in
32.6% to 89.4% of these infections.10,15,16 Gram-positive
cocci, particularly coagulase-negative staphylococci, are
reported to be the predominant blood isolates.10,16-18
Likewise, 13.5% of our patients developed infections during
ECMO use, and 69.1% of these infections were bloodstream
infection. However, S maltophilia and Candida species were
the most common blood isolates. Because a single blood
isolate of coagulase-negative staphylococci without compati-
ble clinical conditions defined by the Centers for Disease Con-
trol was not regarded as a bloodstream infection, this may
explain why coagulase-negative staphylococci were not the
most common blood isolate in our study. In addition, our prac-
tice of antibiotic prophylaxis with vancomycinmay contribute
to this finding.
Risk factors for infections caused by S maltophilia and
Candida species include prolonged hospitalization or inten-
sive care unit stay,19-21 exposure to broad-spectrum antibi-
otics,20-23 and use of central venous catheters.21-23 Thus, it
is not surprising that S maltophilia and Candida species
were the predominant blood isolates in this study, and
significant proportions of causative pathogens of infections
during ECMO use had antibiotic resistance given the fact
that our patients with infections during ECMO use had
a mean duration of hospitalization of 13.2 days before
ECMO initiation. In addition, 37.8% of them had
infections before ECMO initiation, 40.0% required CPR,
and 46.7% required IABP. These clinical conditions1130 The Journal of Thoracic and Cardiovascular Surfurther predisposed patients to prolonged hospital or
intensive care unit stay, broad-spectrum antibiotic exposure,
and placement of multiple central catheters, which subse-
quently led to increased risk of acquiring infections caused
by resistant organisms.
Given highly invasive procedures (eg, ECMO or IABP) in
emergency situations (eg, sudden collapse or worsening re-
spiratory conditions despite full ventilator support), compli-
ance of infection-control precautions might not be perfect. In
addition, immunologic responses of patients with sepsis may
be inappropriate. The use of steroids for acute respiratory
distress syndrome or adrenal insufficiency, body tempera-
ture control, and multiple blood transfusions after cardiac
operations or for coagulopathy during ECMO use can also
interfere with the presentations of infection in patients un-
dergoing ECMO. Thus, we routinely prescribed antimicro-
bial prophylaxis after ECMO initiation, and it is common
to escalate antibiotics immediately and empirically when-
ever infections are suspected. Although these practices
might decrease the occurrence of infections during ECMO
use, they also contribute to the subsequent infections caused
by drug-resistant bacteria and Candida species as a result of
antibiotic selection pressure.
Duration of ECMO use and mechanical complications
have been reported as risk factors for occurrence of infec-
tions during ECMO use,7,8,10,15,16,18,24 and we also had
similar observations. Our patients with autoimmune
disease and receipt of VV mode also had greater
likelihood of infections (Table 4). The association between
autoimmune disease and infections has not been previously
described. Nevertheless, it is plausible that the immunity of
these patients was severely compromised by immunosup-
pressive agents or their diseases, which predispose them to
infections during ECMO use. Before ECMO initiation, 8
of our 10 patients with autoimmune disease received inten-
sified immunosuppression with corticosteroid or cyclophos-
phamide to control their disease exacerbation.
Compared with VV mode, venoarterial mode has long
been considered as a more complex cannulation and associ-
ated with more complications, such as vascular trauma, sys-
temic embolization, and ischemia.25 It is not clear why VVgery c November 2010
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present study. However, because our patients with VV
mode were more likely to require respiratory support, have
infections before ECMO use, and undergo ECMO longer
than those with venoarterial mode (data not shown), it is pos-
sible that the characteristics of patients with VV mode ren-
dered them vulnerable to infections, or that other unknown
or unassessed factors influenced the risk of infections.
Infections during ECMO use have also been identified as
a risk factor for death.7-9,18 However, older age, neurologic,
and vascular complications, but not infections during
ECMO use, were associated with a higher risk for in-
hospital death in our study. Elderly patients usually had
more comorbidities and were more fragile. Therapeutic strat-
egies tended to be supportive in patients in whom neurologic
complications developed during ECMO use (eg, intracranial
hemorrhage or brain death), which might explain why the
likelihood of in-hospital death in older patients or patients
with neurologic complications was greater. Because vascu-
lar complications included dysfunction of distal reperfusion
catheter (91.4%), digital gangrene (12.2%), and require-
ment of fasciotomy (4.3%) (data not shown), the association
between vascular complications and mortality might be due
to inadequate perfusion of distal limbs and its associated
complications.
It should be noted that several studies have described
infections occurring during ECMO use in neonatal and pedi-
atric populations,9,14-18 whereas in adults, only 1 study
explicitly addressed this issue, and its study population
was different from ours.10 Our patient population was larger
(334 patients with a total of 2559 ECMO days vs 71 patients
with a total of 799 ECMO days), was older (mean 51 vs 36.0
years in infected group and 33.3 years in uninfected group),
was hospitalized longer before ECMO initiation (mean 11.3
vs 2.3 days in infected group and 1.6 days in uninfected
group), and underwent ECMO in recent years (1996–2007
vs 1985–1995), primarily for cardiac support (79.6% vs
9.9%). Nevertheless, there were less bloodstream infections
in the present study in terms of both overall rate (14.85 vs
18.8 episodes per 1000 ECMO days) and rates stratified
by the duration of ECMO use (13.83, 23.78, 24.45, and
14.65 vs 9.5, 27.2, 64.5, and 90.9 episodes per 1000
ECMO days for ECMO duration of>2–10,>10–20,>20–
30, and>30 days, respectively). These differences may be
attributable to advances of ECMO technology and critical
care in the current era, different definitions of infections dur-
ing ECMO use (ours was from ECMO initiation to removal
and theirs10 was from 24 hours after initiation to 48 hours
after removal), and multidiscipline experience in our
ECMO team.
Study Limitations
Several weaknesses of our study deserve to be acknowl-
edged. First, information regarding antibiotic use and dura-The Journal of Thoracic and Cartion in patients undergoing ECMO was not available, so we
could not evaluate the effects of antibiotics on the occur-
rence of infections or resistance of causative pathogens. In
addition, variables such as surveillance cultures, nutritional
support, need for and amount of blood transfusion, and ven-
tilation times were not assessed, so their impact on the inci-
dence of infection in the patients receiving ECMO is beyond
the scope of this report. Second, because the lung paren-
chyma could be affected by patients’ underlying pulmonary
or cardiac diseases, it is difficult to distinguish whether
superimposed respiratory tract infections occurred. Thus,
the rate of respiratory tract infections might be underesti-
mated in our surveillance system. Third, data regarding nos-
ocomial infections in intensive care unit patients without
ECMO use who had similar disease severity were not avail-
able, and this precludes our ability to further analyze the im-
pact of ECMO use on the occurrence of infections. Last, the
present study was limited to a single center.CONCLUSIONS
Our study showed that infections during ECMO use oc-
curred in13.5%of an adult population.Bloodstream infection
wasmost common and primarily caused by S.maltophilia and
Candida species. Themajority of the causative pathogens car-
ried antimicrobial resistance. We demonstrated substantial
advancement of ECMO care in adults in the current era and
identified several risk factors associated with occurrence of
infections during ECMO use and in-hospital mortality.
These warrant prospective randomized studies to confirm
our findings.
The authors thank Dr Victor L. Yu of University of Pittsburgh
for the review of this manuscript.References
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TABLE E1. Demographic comparison between patients who died during hospitalization and patients who survived to be discharged
Characteristics Total Death Survival P value
Patient no. 334 228 106
Men,% (n) 68.0 (227) 69.3 (158) 65.1 (69) .443
Age, y (mean  SD) 51  17 54  17 45  16 <.001
16–35 y,% (n) 21.6 (72) 15.8 (36) 34.0 (36) <.001
36–55 y 35.0 (117) 34.2 (78) 36.8 (39) .645
56–75 y 38.6 (129) 43.4 (99) 28.3 (30) .008
76 y 4.8 (16) 6.6 (15) 0.9 (1) .025
Underlying diseases,% (n)
Coronary artery disease 45.2 (151) 52.2 (119) 30.2 (32) <.001
Hypertension 28.7 (96) 32.0 (73) 21.7 (23) .052
Diabetes mellitus 26.3 (88) 30.3 (69) 17.9 (19) .017
Valvular heart disease 13.2 (44) 13.6 (31) 12.3 (13) .738
Cardiomyopathy 11.1 (37) 8.8 (20) 16.0 (17) .049
Transplantation 9.3 (31) 8.8 (20) 10.4 (11) .638
Cerebrovascular accident 6.9 (23) 7.9 (18) 4.7 (5) .286
Malignancy 6.6 (22) 6.6 (15) 6.6 (7) .993
Congenital heart disease 4.5 (15) 4.4 (10) 4.7 (5) .999
End-stage renal disease 4.2 (14) 4.8 (11) 2.8 (3) .580
Autoimmune disease* 3.0 (10) 4.4 (10) 0 (0) .065
Othersy 7.2 (24) 7.5 (17) 6.6 (7) .779
Baseline heart function
NYHA class I 32.5 (82/252) 27.5 (47/171) 43.2 (35/81) .015
NYHA class II 29.0 (73/252) 32.2 (55/171) 22.2 (18/81)
NYHA class III 18.7 (47/252) 22.2 (38/171) 11.1 (9/81)
NYHA class IV 19.8 (50/252) 18.1 (31/171) 23.5 (19/81)
Indication of ECMO use,% (n)
Respiratory support 20.4 (68) 20.6 (47) 19.8 (21) .865
Infection associated 60.3 (41/68) 63.8 (30) 52.4 (11) .373
Non-infection associated 39.7 (27/68) 36.2 (17) 47.6 (10)
Cardiac support 79.6 (266) 79.4 (181) 80.2 (85) .865
Postcardiotomyz 30.1 (80/266) 28.7 (52/181) 32.9 (28/85) .485
Acute myocardial infarction 29.7 (79/266) 35.4 (64/181) 17.6 (15/85) .003
Cardiomyopathy 15.4 (41/266) 13.3 (24/181) 20.0 (17/85) .156
Acute myocarditis 10.5 (28/266) 5.5 (10/181) 21.2 (18/85) <.001
PH and RH failure 2.3 (6/266) 2.8 (5/181) 1.2 (1/85) .712
Septic shock 3.0 (8/266) 3.9 (7/181) 1.2 (1/85) .416
Othersx 9.0 (24/266) 10.5 (19/181) 5.9 (5/85) .221
SD, Standard deviation; NYHA,NewYork Heart Association; ECMO, extracorporeal membrane oxygenation; PH, pulmonary hypertension; RH, right heart. *Autoimmune disease
included systemic lupus erythematosus, Wegener’s granulomatosis, dermatomyositis, antiphospholipid syndrome, and scleroderma with vasculitis. yOthers included trauma, pri-
mary pulmonary hypertension, liver cirrhosis, and chronic obstructive pulmonary disease. zPostcardiotomy ¼ ECMO use for postcardiotomy cardiogenic shock in patients un-
dergoing cardiac operations, including coronary bypass grafting in 40% (32/80), heart transplantation in 25% (20/80), heart valvular operations in 18.8% (15/80), and others
in 16.2% (13/80, including pericardiotomy/pericardiectomy, correction of congenital heart disease, aortic operation, and pulmonary artery endarterectomy); in-hospital mortality
of patients with postcardiotomy ECMO use and those without was 65% (52/80) and 69.4% (129/186), respectively (P ¼ .485); of 52 patients with postcardiotomy ECMO who
died, causes of in-hospital death were worsening heart function in 46.2% (24/52), sepsis after ECMO removal in 13.5% (7/52), bleeding in 11.5% (6/52), and miscellaneous causes
in 28.8% (15/52, including respiratory failure in 4, ventricular tachycardia in 3, unidentifiable causes in 3, hepatic failure in 2, acidosis in 1, compartment syndrome in 1, and
refractory acidosis in 1). xOthers included acute rejection, congenital heart disease, and unidentified cardiac disease
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TABLEE2. Comparison of extracorporealmembrane oxygenation use between patients who died during hospitalization and thosewho survived to
be discharged
Total Death Survival P value
Patient No. 334 228 106
IABP during hospitalization,% (n) 58.4 (195) 60.1 (137) 54.7 (58) .354
CPR during hospitalization,% (n) 49.4 (165) 54.4 (124) 38.7 (41) .008
Infection<1 wk before ECMO,% (n) 19.8 (66) 21.9 (50) 15.1 (16) .144
Severity of disease at ECMO initiation
APACHE II score, mean  SD 17  7 18  7 15  7 <.001
20,% (n) 31.4 (105) 37.3 (85) 18.9 (20) .001
Duration of hospitalization before
ECMO initiation, d, mean  SD
11.3  26.0 12  24 10  30 .522
ECMO use at admission,% (n) 26.9 (90) 25.9 (59) 29.2 (31) .518
1 wk of hospitalization 68.3 (228) 64.0 (146) 77.4 (82) .015
2 and>1 wk of hospitalization 10.2 (34) 13.2 (30) 3.8 (4) .008
>2 wk of hospitalization 21.6 (72) 22.8 (52) 18.9 (20) .415
Mode of ECMO,% (n)
Venoarterial 80.3 (265/330) 81.4 (184) 77.9 (81) .454
Venovenous 17.3 (57/330) 15.5 (35) 21.2 (22) .206
Duration of ECMO, h, mean  SD 184  188 185  191 182  182 .908
184 h and>48 h,% (n) 69.2 (231) 68.4 (156) 70.8 (75) .667
>184 h 30.8 (103) 31.6 (72) 29.2 (31)
Complications,% (n)
Infection 13.5 (45) 14.9 (34) 10.4 (11) .259
Mechanical* 61.1 (204) 62.3 (142) 58.5 (62) .508
Hemorrhagey 49.4 (165) 52.2 (119) 43.4 (46) .134
Neurologicz 17.7 (59) 25.4 (58) 0.9 (1) <.001
Pulmonaryx 6.9 (23) 6.1 (14) 8.5 (9) .430
Cardiac tamponade 9.9 (33) 11.8 (27) 5.7 (6) .078
Metabolick 75.1 (251) 81.1 (185) 62.3 (66) <.001
Vascular{ 41.6 (139) 46.1 (105) 32.1 (34) .016
IABP, Intra-aortic balloon pump; CPR, cardiopulmonary resuscitation; APACHE II, Acute Physiology and Chronic Health Evaluation II; ECMO, extracorporeal membrane
oxygenation; SD, standard deviation. *Mechanical complications included oxygenator failure; pump malfunction; heater dysfunction; clot of oxygenator, hemofilter, and other
sites; connector crack; and so forth. yHemorrhage complications included gastrointestinal hemorrhage, cannulation site bleeding, surgical site bleeding, and hemolysis. zNeurologic
complications included brain death, seizure, and cerebrovascular accident. xPulmonary complications included pneumothorax and pulmonary hemorrhage. kMetabolic complica-
tions included blood glucose level<40 mg/dL or>240 mg/dL, serum pH<7.2 or>7.6, or serum bilirubin level>15 mg/dL. {Vascular complications included digital gangrene,
dysfunction of reperfusion catheter, and fasciotomy
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